Blue Ocean Ventures

The four co-founders — Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz and Thomas Zehnder — share investment authority collectively. The firm does not designate a single managing partner or CIO on its public materials; instead it operates through advisor-level consensus, with de Watteville maintaining a parallel role as Head of Startup Financing at Geneva's FONGIT incubator, which gives him direct line-of-sight into pre-incorporation teams.

Through embedded access to the Swiss federal innovation pipeline. The founders sit inside Innosuisse (the Swiss Confederation's Innovation Promotion Agency) as evaluators and coaches — de Watteville alone has reviewed over 200 high-tech startups through FONGIT and the former CTI program. This positions Blue Ocean to identify companies before they become investment-ready, often 12 to 24 months ahead of a formal funding round.

No. Blue Ocean is a Jersey-registered Limited Partnership fund that pools capital from multiple family offices and high-net-worth individuals. It is not tied to any single family's wealth and operates as a conventional early-stage venture firm with a specialized medical-device mandate.

Blue Ocean executes only direct investments into portfolio companies. The firm acts as either lead investor on rounds or as a syndicated co-investor alongside reputed venture capital firms — the website states explicitly that LPs receive co-investment rights under certain conditions, but there is no fund-of-funds activity.

The firm concentrates on pre-investment-ready startups and first institutional rounds, with pre-money valuations typically between CHF 3 million and CHF 10 million. It monitors promising companies before they are ready for external capital, then organizes the first round. Blue Ocean typically requires a board seat and reserves capital for follow-on rounds.

Emmanuel de Watteville serves simultaneously as Co-Founder and Advisor at Blue Ocean Ventures and as Head of Startup Financing at FONGIT, Geneva's primary technology incubator. This dual role creates a direct pipeline from FONGIT's resident companies into Blue Ocean's deal flow, though the two entities are legally separate.

Much of the portfolio traces back to the Swiss Federal Institutes of Technology. Nikos Stergiopulos, a Blue Ocean Scientific Advisor and EPFL professor, co-founded Rheon Medical (adjustable glaucoma shunts) directly from his laboratory. Similarly, Volumina Medical and Abionic originated from EPFL and ETH Zurich research programs, reflecting the fund's systematic reliance on federal academic research as its primary deal engine.